OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis.

Ilaria MaccoraNiccolò LombardiGiada CrescioliAlessandra BettiolRoberto BonaiutiIlaria PagniniValerio ManiscalcoEdoardo MarraniMaria Vincenza MastroliaClaudia RavaldiRita ConsoliniMarco CattaliniNiccolò LombardiGabriele Simonini

Published in: Rheumatology (Oxford, England) (2021)

Our real-life results seem to confirm the efficacy and safety profile of switching from originator of ADA and ETA to their respective BIOs also in paediatric patients with JIA.

Keyphrases

juvenile idiopathic arthritis
disease activity
intensive care unit
emergency department
rheumatoid arthritis
adverse drug
drug induced